Found 12 matching trials
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
N/AThis is a multicenter screening protocol designed to identify patients with...
Location
Southern Cancer Center
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
N/AThe purpose of SIBYL is to generate clinical validity data for the ability ...
Location
Orchard Healthcare Research Inc.
Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study
N/ACurrent guidelines in non-small cell lung cancer recommend genomic assessme...
Location
Tom Baker Cancer Centre
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
PHASE2This is a Phase 2, randomized, multicenter, double-blind study of the gluta...
Location
University of Alabama at Birmingham
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
PHASE3The goal of this clinical trial is to learn if the application of the chemo...
Location
Charite University, Berlin
Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)
N/ATumor Derived cell free DNA (cfDNA) is increasingly used in the clinic to o...
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
PHASE2This is a phase II trial to examine the efficacy of neratinib plus trastuzu...
Location
Kaiser Permanente-Anaheim
Guardant360® Test-Related Clinical Outcomes in Patients Who Share Medical Records
N/ATo document the clinical outcomes of cancer patients who received the Guard...
Noninvasive vs. Invasive Lung Evaluation
N/ATumor derived cell free DNA (cfDNA) is increasingly used in the clinic to o...
Location
Multiple Locations
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
N/AThe purpose of this registry is to collect data that describes the characte...